Pharmaceutical Companies

A pivotal advancement in cancer treatment unfolds as ENHERTU secures its approval in China, offering a specialized option for patients battling hormone receptor-positive and...

UCB hosted its third Epilepsy Digital Roundtable on December 3, 2025, marking a significant commitment towards enhancing patient outcomes through digital health initiatives. The...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive form of blood cancer that presents characteristics of both leukemia and lymphoma, has long...

Set against an evolving landscape of therapeutic innovation, Jazz Pharmaceuticals has slated significant investor events for early January 2026, offering stakeholders an opportunity to...

In the realm of rare diseases, the anticipation of breakthrough treatments often sparks hope among affected individuals and medical communities. The FALKON trial, a...

The European Medicines Agency (EMA) recently announced significant updates on drug labelling exemptions across multiple pharmaceutical products. These exemptions, granted under Article 63 of...

Ovarian cancer patients have received a promising update with the launch of the DESTINY-Ovarian01 phase 3 trial. The trial aims to establish the...

In a landmark development, the U.S. Food and Drug Administration (FDA) has expanded treatment options for gonorrhea by approving two new oral medications, Nuzolvence...

Maxching the anticipation of major pharmaceutical innovations, Healthy Yuan Pharmaceuticals has seen a notable development with the approval of Marpasisavir capsules (trade name: Yilikang®)...

Stepping onto the forefront of oncology breakthroughs, Roche has unveiled promising new data for Lunsumio® (mosunetuzumab) at the American Society of Hematology Annual Meeting...

In a significant advancement for healthcare providers, Hikma Pharmaceuticals has introduced TYZAVAN™, a pioneering vancomycin injection solution ready for immediate use. This new product...

In a notable assembly held on October 8-9, 2025, the Committee for Advanced Therapies (CAT) convened to assess ongoing applications surrounding Advanced Therapy Medicinal...

The European Commission has granted approval for Gazyva™/Gazyvaro™ (obinutuzumab), marking a pivotal stride for Roche in the treatment of lupus nephritis across Europe. Lupus...

Sanofi, a global leader in biopharmaceuticals, has announced a strategic move that could significantly enhance its respiratory vaccine portfolio. By acquiring the biotech firm...

Navigating the complex landscape of rare diseases, the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) plays a crucial role in evaluating and...